tetano
Editor, Senior Moderator
Proc Natl Acad Sci U S A
. 2025 Nov 11;122(45):e2409565122.
doi: 10.1073/pnas.2409565122. Epub 2025 Nov 3. A multivalent nanobody-drug conjugate to prevent and treat influenza virus infections
Thibault J Harmand[SUP] #[/SUP][SUP] 1 [/SUP], Laura Pietrok[SUP] #[/SUP][SUP] 1 [/SUP], Helen Rich[SUP] 1 [/SUP], Rhogerry Deshycka[SUP] 1 [/SUP], Laney Flanagan[SUP] 1 [/SUP], Aaron Accardo[SUP] 1 [/SUP], Novalia Pishesha[SUP] 2 3 [/SUP], Hidde L Ploegh[SUP] 4 [/SUP]
Affiliations
We describe the production and use of nanobody drug conjugates that comprise of VHH[SUB]kappa[/SUB], a nanobody that recognizes mouse immunoglobulin kappa light chains, and one or more copies of the small molecule influenza virus neuraminidase (NA) inhibitor, zanamivir. Such compounds achieve half-life extension of zanamivir, while recruiting polyclonal immunoglobulins of all isotypes regardless of specificity to infected cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cellular cytotoxicity. Since the influenza A virus (IAV) NA is a tetramer, we produced VHH[SUB]kappa[/SUB] adducts with 1, 2, or 4 zanamivir molecules attached in a site-specific manner, to allow multivalent engagement of NA. Administration of a VHH[SUB]kappa[/SUB] adduct modified with 4 zanamivir molecules (VHH[SUB]kappa[/SUB]-Zan[SUB]4[/SUB]) was ~10-fold more potent in protection against infection with IAV than VHH[SUB]kappa[/SUB]-Zan carrying only a single zanamivir molecule. VHH[SUB]kappa[/SUB]-Zan[SUB]4[/SUB] can be given intranasally to confer full protection against a lethal IAV challenge. The neutralizing antibody titers in the respiratory mucosa and in the circulation, as well as the serum IgG antibody response against the hemagglutinin and nucleoprotein, are higher in VHH[SUB]kappa[/SUB]-Zan[SUB]4[/SUB] treated mice that survived the lethal challenge than in controls infected with a sublethal dose of virus. VHH[SUB]kappa[/SUB]-Zan[SUB]4[/SUB] affords protection even when given intranasally weeks prior to a challenge with a lethal dose of IAV. This type of adduct can therefore be applied prophylactically and therapeutically and does not require prior immunization for protection against a lethal dose of IAV.
Keywords: bioconjugate; influenza; nanobody drug conjugates.
. 2025 Nov 11;122(45):e2409565122.
doi: 10.1073/pnas.2409565122. Epub 2025 Nov 3. A multivalent nanobody-drug conjugate to prevent and treat influenza virus infections
Thibault J Harmand[SUP] #[/SUP][SUP] 1 [/SUP], Laura Pietrok[SUP] #[/SUP][SUP] 1 [/SUP], Helen Rich[SUP] 1 [/SUP], Rhogerry Deshycka[SUP] 1 [/SUP], Laney Flanagan[SUP] 1 [/SUP], Aaron Accardo[SUP] 1 [/SUP], Novalia Pishesha[SUP] 2 3 [/SUP], Hidde L Ploegh[SUP] 4 [/SUP]
Affiliations
- PMID: 41183201
- DOI: 10.1073/pnas.2409565122
We describe the production and use of nanobody drug conjugates that comprise of VHH[SUB]kappa[/SUB], a nanobody that recognizes mouse immunoglobulin kappa light chains, and one or more copies of the small molecule influenza virus neuraminidase (NA) inhibitor, zanamivir. Such compounds achieve half-life extension of zanamivir, while recruiting polyclonal immunoglobulins of all isotypes regardless of specificity to infected cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cellular cytotoxicity. Since the influenza A virus (IAV) NA is a tetramer, we produced VHH[SUB]kappa[/SUB] adducts with 1, 2, or 4 zanamivir molecules attached in a site-specific manner, to allow multivalent engagement of NA. Administration of a VHH[SUB]kappa[/SUB] adduct modified with 4 zanamivir molecules (VHH[SUB]kappa[/SUB]-Zan[SUB]4[/SUB]) was ~10-fold more potent in protection against infection with IAV than VHH[SUB]kappa[/SUB]-Zan carrying only a single zanamivir molecule. VHH[SUB]kappa[/SUB]-Zan[SUB]4[/SUB] can be given intranasally to confer full protection against a lethal IAV challenge. The neutralizing antibody titers in the respiratory mucosa and in the circulation, as well as the serum IgG antibody response against the hemagglutinin and nucleoprotein, are higher in VHH[SUB]kappa[/SUB]-Zan[SUB]4[/SUB] treated mice that survived the lethal challenge than in controls infected with a sublethal dose of virus. VHH[SUB]kappa[/SUB]-Zan[SUB]4[/SUB] affords protection even when given intranasally weeks prior to a challenge with a lethal dose of IAV. This type of adduct can therefore be applied prophylactically and therapeutically and does not require prior immunization for protection against a lethal dose of IAV.
Keywords: bioconjugate; influenza; nanobody drug conjugates.